Allurion Technologies, Inc. (ALUR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Allurion Technologies, Inc. stock (ALUR) is currently trading at $0.51. Allurion Technologies, Inc. PS ratio (Price-to-Sales) is 0.52. Analyst consensus price target for ALUR is $5.50. WallStSmart rates ALUR as Sell.
- ALUR PE ratio analysis and historical PE chart
- ALUR PS ratio (Price-to-Sales) history and trend
- ALUR intrinsic value — DCF, Graham Number, EPV models
- ALUR stock price prediction 2025 2026 2027 2028 2029 2030
- ALUR fair value vs current price
- ALUR insider transactions and insider buying
- Is ALUR undervalued or overvalued?
- Allurion Technologies, Inc. financial analysis — revenue, earnings, cash flow
- ALUR Piotroski F-Score and Altman Z-Score
- ALUR analyst price target and Smart Rating
Allurion Technologies, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Allurion Technologies, Inc. (ALUR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, eps growth, institutional own.. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Allurion Technologies, Inc. (ALUR) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 7119.00% year-over-year
57.01% held by institutions, strong professional interest
Supporting Valuation Data
Allurion Technologies, Inc. (ALUR) Areas to Watch (4)
Losing money on operations
Revenue declining -50.50%, a shrinking business
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Allurion Technologies, Inc. (ALUR) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (0.52) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 7119.00%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Profit Margin. Growth concerns include Revenue Growth at -50.50%, which may limit upside. Profitability pressure is visible in Operating Margin at -362.30%, Profit Margin at -187.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -362.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -50.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALUR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALUR's Price-to-Sales ratio of 0.52x trades 17% below its historical average of 0.63x (47th percentile). The current valuation is 77% below its historical high of 2.25x set in Jan 2025, and 479% above its historical low of 0.09x in Nov 2024. Over the past 12 months, the PS ratio has compressed from ~1.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Allurion Technologies, Inc. (ALUR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Allurion Technologies, Inc. is in a turnaround phase, with management focused on restoring profitability. Revenue reached 17M with 51% decline year-over-year. The company is currently unprofitable, posting a -187.9% profit margin.
Key Findings
Revenue contracted 51% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -187.9% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Allurion Technologies, Inc..
Bottom Line
Allurion Technologies, Inc. is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Allurion Technologies, Inc.(ALUR)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. The company is headquartered in Natick, Massachusetts.